Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis

Blood

Volumn 122, Issue 7, 2013, Pages 1203-1213

  Wölfl, Matthias ^a   Schwinn, Stefanie ^a   Yoo, Young Eun ^a   Reß, Marie L ^a   Braun, Matthias ^a   Chopra, Martin ^a,b   Schreiber, Susanne C ^a   Ayala, Victor I ^c   Ohlen, Claes ^c   Eyrich, Matthias ^a,b   Beilhack, Andreas ^a,b   Schlegel, Paul G ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Interdisciplinary Center for Clinical Research   (Germany)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BOSUTINIB; DASATINIB; GAMMA INTERFERON; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 27; MELAN A; NILOTINIB; PROSTAGLANDIN E2; SARACATINIB; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW CELL; CD8+ T LYMPHOCYTE; CELL MATURATION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG BLOOD LEVEL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LEUKAPHERESIS; LYMPHOCYTE PROLIFERATION; MAXIMUM PLASMA CONCENTRATION; MONOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RHESUS MONKEY; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION;

ANIMALS; CELLS, CULTURED; DENDRITIC CELLS; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MACACA MULATTA; MICE; MYELOID CELLS; NF-KAPPA B; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; T-LYMPHOCYTES; THIAZOLES; TOLL-LIKE RECEPTORS;

EID: 84887190083     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-488072     Document Type: Article

References (45)

1. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109(6):2303-2309.
2. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer. 2004;4(6):470-480.
3. Lowell CA. Src-family kinases: rheostats of immune cell signaling. Mol Immunol. 2004; 41(6-7):631-643.
4. Steegmann JL, Cervantes F, le Coutre P, Porkka K, Saglio G. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma. 2012;53(12):2351-2361.
5. Kreutzman A, Juvonen V, Kairisto V, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010; 116(5):772-782.
6. Kreutzman A, Ladell K, Koechel C, et al. Expansion of highly differentiated CD81 T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia. 2011;25(10):1587-1597.
7. Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128-2137.
8. Kim DH, Kamel-Reid S, Chang H, et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica. 2009;94(1):135-139.
9. Sillaber C, Herrmann H, Bennett K, et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest. 2009;39(12):1098-1109.
10. Das J, Chen P, Norris D, et al. 2-aminothiazole as a novel kinase inhibitor template. Structureactivity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem. 2006;49(23): 6819-6832.
11. Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008;111(3):1366-1377.
12. Weichsel R, Dix C, Wooldridge L, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008; 14(8):2484-2491. doi: 10.1158/1078-0432.CCR-07-4393.
13. Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol. 2008;127(3):330-339.
14. Rix U, Hantschel O, Dürnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007; 110(12):4055-4063.
15. Montero JC, Seoane S, Ocaña A, Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res. 2011;17(17):5546-5552. doi: 10.1158/1078-0432. CCR-10-2616.
16. Melnick JS, Janes J, Kim S, et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci USA. 2006;103(9):3153-3158.
17. Wölfl M, Langhammer F, Wiegering V, Eyrich M, Schlegel PG. Dasatinib medication causing profound immunosuppression in a patient after haploidentical SCT: functional assays from whole blood as diagnostic clues. Bone Marrow Transplant. 2013;48(6):875-877.
18. Seggewiss R, Price DA, Purbhoo MA. Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update. Cytotherapy. 2008;10(6):633-641.
19. Appel S, Boehmler AM, Grünebach F, et al. Imatinib mesylate affects the development and function of dendritic cells generated from CD341 peripheral blood progenitor cells. Blood. 2004; 103(2):538-544.
20. Wang H, Cheng F, Cuenca A, et al. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD41 T-cell tolerance. Blood. 2005;105(3):1135-1143.
21. Schwarzbich MA, Gutknecht M, Salih J, et al. The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors. Cancer Immunol Immunother. 2012;61(2):193-202.
22. Wölfl M, Merker K, Morbach H, et al. Primed tumor-reactive multifunctional CD62L1 human CD81 T cells for immunotherapy. Cancer Immunol Immunother. 2011;60(2):173-186.
23. Lissina A, Ladell K, Skowera A, et al. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods. 2009;340(1): 11-24.
24. Romero P, Valmori D, Pittet MJ, et al. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev. 2002;188: 81-96.
25. Zippelius A, Pittet MJ, Batard P, et al. Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med. 2002; 195(4):485-494.
26. Pittet MJ, Valmori D, Dunbar PR, et al. High frequencies of naive Melan-A/MART-1-specific CD8(1) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med. 1999;190(5):705-715.
27. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007;7(5):345-356.
28. Curtsinger JM, Mescher MF. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol. 2010;22(3):333-340.
29. Hayes MP, Wang J, Norcross MA. Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes. Blood. 1995;86(2):646-650.
30. Ma X, Chow JM, Gri G, et al. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J Exp Med. 1996;183(1): 147-157.
31. Appel S, Balabanov S, Brümmendorf TH, Brossart P. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells. 2005;23(8):1082-1088.
32. Bowen WS, Minns LA, Johnson DA, Mitchell TC, Hutton MM, Evans JT. Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist. Sci Signal. 2012;5(211):ra13.
33. Schäkel K, Kannagi R, Kniep B, et al. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity. 2002;17(3):289-301.
34. Schäkel K, von Kietzell M, Hänsel A, et al. Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes. Immunity. 2006;24(6): 767-777.
35. Overwijk WW, Tsung A, Irvine KR, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998;188(2):277-286.
36. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov. 2012;11(3):215-233.
37. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy - revisited. Nat Rev Drug Discov. 2011;10(8):591-600.
38. Lee KC, Ouwehand I, Giannini AL, Thomas NS, Dibb NJ, Bijlmakers MJ. Lck is a key target of imatinib and dasatinib in T-cell activation. Leukemia. 2010;24(4):896-900.
39. Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension. Chest. 2012; 141(1):210-221.
40. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation. 2010;122(9):920-927.
41. Fei F, Yu Y, Schmitt A, et al. Dasatinib inhibits the proliferation and function of CD41CD251 regulatory T cells. Br J Haematol. 2009;144(2): 195-205.
42. Yang Y, Liu C, Peng W, et al. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood. 2012;120(23): 4533-4543.
43. Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23(8): 1398-1405.
44. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol. 2007;7(3):179-190.
45. Raghuwanshi D, Mishra V, Suresh MR, Kaur K. A simple approach for enhanced immune response using engineered dendritic cell targeted nanoparticles. Vaccine. 2012;30(50):7292-7299.